论文部分内容阅读
2010年9月17日,美国食品药品管理局(FDA)宣布:为评估吡格列酮(pioglitazone)与增加膀胱癌风险相关的安全性,正在对吡格列酮进行为期10年的流行病学证据调查。吡格列酮于1999年经FDA批准,用于饮食疗法或运动疗法未达到理想疗效的成人2型糖尿病患者的血糖水平控制。其降低糖化血
On September 17, 2010, the U.S. Food and Drug Administration (FDA) announced that pioglitazone is undergoing a 10-year epidemiological investigation to assess the safety of pioglitazone in increasing the risk of bladder cancer. Pioglitazone was approved by the FDA in 1999 for blood glucose level control in adults with type 2 diabetes who did not achieve the desired therapeutic effect with diet or exercise therapy. It reduces glycated blood